Biotech Briefs: Innogen Pharmaceuticals, Arcera, Windward Bio, Marrow Therapeutics & GeneDx 

The latest from small and Emerging Pharma companies featuring Innogen Pharmaceuticals,  Arcera Life Sciences, Windward Bio, Marrow Therapeutics and GeneDx. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Innogen, Arcera in $1-Bn Deal for Fusion Protein GLP-1 
* Windward Bio Raises $300 M in IPO, Warrants for Long-Acting Antibodies Pipeline
* Marrow Therapeutics Raises $173 M for Bone Marrow Disorder Genetic Drugs 
* GeneDx Appoints New CEO 


Innogen, Arcera in $1-Bn Deal for GLP-1 Fusion Protein 
Innogen Pharmaceuticals, a Hong Kong-based bio/pharmaceutical company, has entered into an exclusive licensing and commercialization agreement with Arcera Life Sciences, an Abu Dhabi, United Arab Emirates-based bio/pharmaceutical company for the development and commercialization of Innogen’s efsubaglutide alfa, a glucagon-like peptide-1 (GLP-1) receptor agonist fusion protein approved in China for treating Type 2 diabetes, in a deal worth up to more than $1 billion ($38 million upfront and sales-based milestone payments and tiered royalties). The drug is also being evaluated for treating obesity.  

Under the agreement, Arcera will obtain exclusive rights to efsubaglutide alfa in selected countries in Africa, Latin America, the Middle East, and Eastern Europe while Innogen retains the relevant rights in the rest of the world. Innogen will receive $38 million in upfront and near-term milestone payments, including a non-refundable upfront payment of $15 million, as well as sales milestone payments and tiered royalties at rates of up to double-digit percentage based on aggregate annual net sales of the product. The total potential deal value is over $1 billion. 

Source: Innogen Pharmaceuticals 


Windward Bio Raises $300 M in IPO, Private Placement for Long-Acting Antibodies Pipeline  
Windward Bio, a Basel, Switzerland-based clinical-stage bio/pharmaceutical company focused on respiratory and dermatologic diseases, has raised $251.2 million in gross proceeds from its initial public offering as well as $50 million in a concurrent private placement. 

The company’s lead product candidate, WIN378, is a fully human monoclonal antibody designed to inhibit thymic stromal lymphopoietin (TSLP), a molecule involved in airway inflammation. It is in Phase II/III development for treating severe uncontrolled asthma and in a Phase III study for treating chronic obstructive pulmonary disease. Windward’s second product candidate, WIN027, is an ultra-long-acting bispecific antibody targeting TSLP and interleukin-13 and is currently in a Phase I healthy volunteer study. 

Source: Windward Bio 


Marrow Therapeutics Raises $173 M for Bone Marrow Disorder Genetic Drugs 
Marrow Therapeutics, a Watertown, Massachusetts-based bio/pharmaceutical company developing bone marrow-targeted therapies to treat severe blood disorders, has announced its launch by raising a combined $173 million in Series A and B funding.  

Marrow is developing engineered antibodies through its bone-marrow-targeting platform. Marrow’s engineered antibodies target the transferrin receptor in bone marrow and deliver therapeutic payloads to bone marrow to treat severe blood disorders.  

The company’s lead candidate, MAR-101, currently in investigational new drug-enabling studies, is designed to treat both sickle-cell disease and beta thalassemia, an inherited blood disorder that affects the body’s ability to make hemoglobin, by decreasing BCL11a and reactivating fetal hemoglobin production. 

Source: Marrow Therapeutics 


GeneDx Appoints New CEO 
GeneDx, a genomics and diagnostics company specializing in rare diseases, has appointed Everett Cunningham, currently President and Chief Executive Officer (CEO) at Quanterix, a company focused on biomarker science, as CEO and a member of the Board, effective on or before December 15, 2026.  

Cunningham succeeds Katherine Stueland, who has announced that she will step down as CEO and as a member of the Board when Cunningham joins GeneDx. Stueland will remain with GeneDx in an advisory capacity through January 31, 2027,  to support a smooth transition. 

Cunningham has more than 35 years of experience building and leading commercial organizations across diagnostics, genomics, medical technology and pharmaceuticals, including senior roles at Illumina, a sequencing and array technology company, Exact Sciences, a provider of cancer tests, GE Healthcare, Quest Diagnostics, and Pfizer. 

Source: GeneDx